lenvatinib/Cas:417716-92-8 /lenvatinib Mesylate 857890-39-2 CAS NO.417716-92-8
- FOB Price: USD: 4.00-5.00 /Metric Ton Get Latest Price
- Min.Order: 25 Metric Ton
- Payment Terms: L/C,D/P,T/T,
- Available Specifications:
100(1-25)Metric Ton100(100-500)Metric Ton
- Product Details
Keywords
- 417716-92-8
- 857890-39-2
- lenvatinib
Quick Details
- ProName: lenvatinib/Cas:417716-92-8 /lenvatinib...
- CasNo: 417716-92-8
- Molecular Formula: C21H19ClN4O4·CH4O3S
- Appearance: White or off white powder
- Application: It is suitable for chemical industry s...
- DeliveryTime: ccording to the actual situation
- PackAge: 100g/bag 1kg/bag 25kg/barrels
- Port: Shanghai port, shenzhen port, tianjin ...
- ProductionCapacity: 100 Metric Ton/Day
- Purity: 99%
- Storage: 2 ℃, 25 ℃ dry dark cold storage
- Transportation: Air freight; shipping;DHL;FEDEX;TNT…
- LimitNum: 25 Metric Ton
- Related Substances: Refer to the details
- Residue on Ignition: Refer to the details
- Heavy Metal: ≤20ppm
- Valid Period: 24 month
- Total protein content: 99%
Superiority
Lovastinib E7080
4-[3- chloro -4- (cyclopropyl amino carbonyl) amino phenoxy]-7- methoxy -6- quinoline formamide
Lovastatin
English Name: lenvatinib
English aliases: E7080, E7080; Lenvatinib (E7080); 4-[3-chloro-4-(cyclopropylcarbamoylamino) phenoxy]-7-methoxyquinoline-6-carboxamide; Lenvatinib;
CAS: 417716-92-8
Molecular formula: C21H19ClN4O4
Molecular weight: 426.85300
Exact mass: 426.10900 PSA:115.57000 LogP:5.23610
Density: 1.469g/cm3
Boiling point: 627.242 C at 760 mmHg
Flash point: 333.144 x C
Refractive index: 1.697
Content: 99.5%
Purpose: anticancer drugs for liver cancer (for scientific research only).
E7080 (Lenvatinib) is a multi-target inhibitor. It is effective on the expression of VEGFR2 (KDR)/VEGFR3 (Flt-4)*** and IC50 is 4 nM/5.2. It has a slightly weaker effect on the expression of VEGFR1/Flt-1. The selectivity of PDGFRa/beta is about 10 times higher than that of the expression of FGFR1.
In vitro study: E7080 effectively inhibited angiogenesis and significantly inhibited VEGF/KDR and SCF/KIT signaling pathways. According to in vitro receptor tyrosine and serine/threonine kinase experiments, when E7080 inhibited Flt-1, KDR and Flt-4, IC50 was 22, 4.0 and 5.2 nM, respectively. In addition to these kinases, E7080 also inhibits both fibroblast growth factor 1 and PDGFR tyrosine kinases. When acting on fibroblast growth factor 1, PDGFR alpha and PDGFR beta, IC50 is 46, 51 and 100 nM, respectively. [1] E7080 acted on HUVECs stimulated by vascular endothelial growth factor and vascular endothelial growth factor-C respectively, effectively inhibiting phosphorylation of vascular endothelial growth factor R2 and vascular endothelial growth factor R3, IC50 being 0.83 nM and 0.36 nM, respectively. Recent studies have shown that treatment with 1um and 10um M E7080 significantly inhibits cell migration and invasion by inhibiting the signal pathways of FGFR and PDGFR.
In vivo studies: E7080 was administered orally at doses of 30 and 100 mg to treat H146 transplanted tumor model, inhibiting the growth of H146 tumor. This effect was dose-dependent, and led to tumor decline at doses of 100 mg. Moreover, E7080 at a dose of 100 mg reduced microvessel density more than those treated with anti-VEGF antibody and Imatinib.
Characteristics: E7080 is an effective oral multitarget kinase inhibitor.
Details